May 09, 2025

Childhood brain tumors develop early in highly specialized nerve cells

Childhood brain tumors develop early in highly specialized nerve cells

Medulloblastomas, childhood brain tumors in children, are thought to develop between the first trimester of pregnancy and the end of the first year of life. Researchers at the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have now published their findings in the journal Nature. They analyzed the genetic changes of each individual cancer cell in tumor samples in order to reconstruct which genetic changes occur first during tumor development and when.

The Hopp Children’s Cancer Center Heidelberg (KiTZ) is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and the University of Heidelberg (Uni HD).

MRT Image of a medulloblastoma in the cerebellum of a child. Source: D. Ghasemi/KiTZ

Medulloblastoma is one of the most common malignant tumors of the central nervous system (CNS) in children and adolescents. It develops in the area of the cerebellum, which is responsible for movement coordination, among other things. Medulloblastomas enlarge rapidly, often grow into surrounding tissue and can also form metastases. The wide variety of this tumor group also makes it difficult to find the right treatment. 

A team of researchers at the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) has now investigated exactly where and when the most aggressive subgroups of these tumors develop in so-called single cell analyses. “We have genetically characterized the many thousands of individual cells from the tumor samples of numerous young patients with medulloblastoma,” explains Konstantin Okonechnikov, first author of the study from KiTZ and DKFZ. “This technology allows us to obtain a high-resolution picture of the genetic make-up within a tumor, so that we can reconstruct its developmental history fairly accurately.” 

Accordingly, there are “early” and “late” genetic changes within a tumor. Based on the distribution of the genetic changes across the various tumor cell clones, the scientists were able to reconstruct the development of the tumor. The study shows that the particularly aggressive medulloblastomas of subgroups three and four probably develop between the first trimester of pregnancy and the end of the first year of life. The origin of the tumor development are the precursor cells of highly specialized nerve cells, the so-called unipolar brush cells of the cerebellum, which also develop between the first trimester of pregnancy and the end of the first year of life. Large rearrangements of entire chromosomes or chromosome arms take place in these cells, presumably initially by chance, as the present results show: The cells loose or gain certain chromosomes.

“We assume that the early loss or gain of certain chromosomes is the first step in tumor development and that these occur many years before the clinical symptoms appear,” says Lena Kutscher from KiTZ and DKFZ, who led the study together with Stefan Pfister, Director at KiTZ, Head of Department at DKFZ and paediatric oncologist at Heidelberg University Hospital (UKHD).

Only the later tumor cells carry the already known duplications or alterations of the cancer genes MYC, MYCN or PRDM6 that are typical for these types of medulloblastoma. “We therefore assume that these cancer genes are responsible for the progressive tumor growth and also for the metastasis and therapy resistance that occurs, but not for the development of the tumor,” says Lena Kutscher.

Lena Kutscher explains what these results could mean for diagnosis and treatment: “If we succeed in developing sufficiently sensitive methods in the future to detect these early changes, for example as DNA fragments in the blood, this could form the basis for possible early detection in newborns and infants.”

Original publication
K. Okonechnikov et al.: Oncogene aberrations drive medulloblastoma progression, not initiation. In: Nature (Online Publication 7th of May 2025). DOI: 10.1038/s41586-025-08973-5

An Image for this press release is available for download at: 
https://www.kitz-heidelberg.de/fileadmin/_processed_/c/7/csm_240104-MBEN_MRT_9b7d579b3e.png

Caption: 
MRT Image of a medulloblastoma in the cerebellum of a child.

Note on use of images related to press releases 
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: “Source: D. Ghasemi/KiTZ”.
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ’s Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse@dkfz.de). Any commercial use is prohibited. 

Our latest News

discover more
PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

World Novelty: Artificial HPL Solution First Artificial Human Platelet Lysate BioScience Raises the Bar in Cell Culture Technology with artificial HPL PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. In partnership with the Korean biotech DewCell Biotherapeutics, PL BioScience […]

EditCo Bio and Promega partner to usher in a new era of biologically relevant cell-based research

EditCo Bio and Promega partner to usher in a new era of biologically relevant cell-based research

More Information in German below. EditCo Bio und Promega schließen Partnerschaft, um eine neue Ära biologisch relevanter zellbasierter Forschung einzuläuten Redwood City, CA, USA. (12. Mai 2025) EditCo Bio, Inc. hat eine strategische Lizenzvereinbarung mit der Promega Corporation bekannt gegeben, die EditCo den Zugang zu den Technologien HiBiT, HaloTag® und NanoLuc® von Promega ermöglicht. Diese fortschrittlichen […]

Affimed Announces Filing for the Opening of Insolvency Proceedings

Affimed Announces Filing for the Opening of Insolvency Proceedings

MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the “Company”) […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp